Researchers at Children's Hospital of Philadelphia (CHOP) have developed a proof-of-concept treatment for blood disorders like sickle cell disease and beta-thalassemia that could raise hemoglobin levels by activating production of both fetal and adult hemoglobin. Using a viral vector engineered to reactivate fetal hemoglobin production, suppress mutant hemoglobin, and supply functional adult hemoglobin, the researchers developed an approach that could produce more hemoglobin through a single vector. The results were published in Haematologica.
The study demonstrates for the first time that a problem with angiogenesis (the mechanism by which new blood vessels are produced) causes the destruction of capillaries and, therefore, a decrease in the supply of nutrients and oxygen to the brain.
Antibodies aren't the only immune cells needed to fight off COVID-19 -- T cells are equally important and can step up to do the job when antibodies are depleted, suggests a new Penn Medicine study of blood cancer patients with COVID-19 published in Nature Medicine.
A mouse model was generated to mimic the condition of vitamin B6 (VB6) deficiency observed in a subtype of patients with schizophrenia by feeding with a VB6-lacking diet. The noradrenergic system in the brain of VB6-deficient mice was enhanced, leading to social deficits and cognitive impairment. Inhibiting the excessive noradrenaline (NA) release by VB6 supplementation into the brain or treatment with ?2A adrenoreceptor agonist guanfacine suppressed the increased NA metabolism and ameliorated the behavioral deficits.
Blocked blood vessels in the brains of stroke patients prevent oxygen-rich blood from getting to cells, causing severe damage. Plants and some microbes produce oxygen through photosynthesis. What if there was a way to make photosynthesis happen in the brains of patients? Now, researchers reporting in ACS' Nano Letters have done just that in cells and in mice, using blue-green algae and special nanoparticles, in a proof-of-concept demonstration.
For the first time, researchers can quantitatively predict blood flow conditions that likely cause pathological behavior of the human blood protein von Willebrand factor. Predictions from this new method of simulation, developed at Lehigh University, can be used to optimize the design of left ventricular assist devices used in heart failure patients. It could also improve diagnosis and treatment of von Willebrand disease, the most common inherited bleeding disorder in the U.S. (per CDC).
A rare syndrome has been observed in people following vaccination against Covid-19. This involves thrombosis at unusual sites in the body, associated with a low thrombocyte count and a clotting disorder. In medical jargon, this syndrome is referred to as VITT (vaccine-induced thrombotic thrombocytopenia). Doctors at MedUni Vienna and Vienna General Hospital have now successfully treated an acute instance of this syndrome.
An international team of researchers has analyzed the function of the histone demethylase KDM5A in multiple myeloma, one of the three major hematological cancers, and clarified the mechanism by which it promotes myeloma cell proliferation. They also developed a novel KDM5 inhibitor and showed that it inhibits cancer cell growth in a myeloma mouse model. The researchers expect that new therapies targeting KDM5A will be developed in the future.
A new method to analyse the blood thinning drug Heparin has been developed that can pinpoint contaminants more accurately and quickly, providing greater quality control and safety.
Scientists show for the first time that the primary cilium - a sensing 'organ' of cells - helps the cells that form the lymphatic vessels of mammals to grow into a functional and locally responsive network, not only during prenatal development but also during inflammation and wound healing. This discovery, in a study by the open access publisher Frontiers, could inspire new medical therapies.